ADORA2A and neoplasm: In preclinical animal models, targeting A2AR, the receptor for adenosine, with a pharmacological inhibitor SCH58261 led to a significant decrease in tumor growth and reduced Tregs while enhancing Teff cell activity in a spontaneous Cre/lox HNSCC model (68).